1. Home
  2. MED vs HURA Comparison

MED vs HURA Comparison

Compare MED & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MEDIFAST INC

MED

MEDIFAST INC

HOLD

Current Price

$12.58

Market Cap

120.6M

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.50

Market Cap

144.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MED
HURA
Founded
1980
2009
Country
United States
United States
Employees
N/A
22
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
120.6M
144.3M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
MED
HURA
Price
$12.58
$2.50
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$12.00
$9.50
AVG Volume (30 Days)
175.0K
737.8K
Earning Date
05-04-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$934,842,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.22
$0.41
52 Week High
$15.37
$3.90

Technical Indicators

Market Signals
Indicator
MED
HURA
Relative Strength Index (RSI) 64.79 54.67
Support Level $9.91 $2.26
Resistance Level $14.41 $2.63
Average True Range (ATR) 0.66 0.24
MACD 0.02 -0.01
Stochastic Oscillator 73.50 58.57

Price Performance

Historical Comparison
MED
HURA

About MED MEDIFAST INC

Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: